RCS - Avacta Group PLC - Shortlisted for AIM Awards Technology of the Year

AvactaAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250909:nRSI5693Ya&default-theme=true

RNS Number : 5693Y  Avacta Group PLC  09 September 2025

Avacta's pre|CISION(®) Platform Shortlisted for the Technology of the Year
Award at the AIM Awards

 

LONDON AND PHILADELPHIA - September 9, 2025 - Avacta Group plc (AIM: AVCT) a
life sciences company developing innovative, targeted oncology drugs, is
pleased to announce today that its pre|CISION(®) platform has been
shortlisted for the AIM Technology of the Year Award. The AIM Awards is the
flagship event for AIM and is held annually, in London, to celebrate success
and achievement amongst the world's fastest growing publicly quoted companies.
The Awards identify the quoted companies and entrepreneurs who have harnessed
AIM to help them fulfil their ambition and growth potential in the last twelve
months. The Awards will be distributed at the event on October 1, 2025.

 

Christina Coughlin, CEO of Avacta commented:

"We are delighted to be on the shortlist for Technology of the Year among
companies listed on the AIM market. Our pre|CISION(®) technology  changes
the way that potent cancer therapies are delivered to patients, where the drug
is silent in the bloodstream yet active in the tumor, allowing cancer cells to
be targeted while preserving patient vitality. We look forward to the event
next month."

 

 

-Ends-

 

For further information from Avacta, please contact:

 

 Peel Hunt (Nomad and Joint Broker)                          www.peelhunt.com (http://www.peelhunt.com)

 James Steel / Chris Golden

 Panmure Liberum (Joint Broker)                             www.panmureliberum.com (http://www.panmureliberum.com)

 Emma Earl / Will Goode / Mark Rogers

 Zeus (Joint Broker)                                        www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry

 Dominic King

 ICR Healthcare (Europe/UK media and investors)              avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 Investor Contact                                           renee@thrustsc.com (mailto:renee@thrustsc.com)

 Renee Leck

 THRUST Strategic Communications

 Media Contact                                              Carly@carlyscadutoconsulting.com

                                                          (https://www.globenewswire.com/Tracker?data=YG-jwixFWaHByFwlhEr4NbVmhGc9YbrV0ozbiHY-33jDG-KDtaZDvqBLS4-5RgIi5zejtwvrLPO1U6xSYlV9BnK-dIegbuZft6wwj-ugstEWYrPDSrd9NwgKYBdm1l9Ty6VSa1gsRJqxeLaMfUN-easXzPVocBafm0xbzTKFahId-T7w4WgPYGYfKdFh6MGXNNniX0b0LrpQwjqHYj_mTmjerN3nRW6pwlbWejQ6wZCns0oke-U-WA7CB-Z2CD1ObedcWrqwKYgQwTY1NxAOLXtmHTL3VJ7HZ4Z3K9ZhB_2_vgbo4aKKTppE6l1bjU2w)
 Carly Scaduto

 Carly Scaduto Consulting

 

 

About Avacta - www.avacta.com (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary payload delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent payloads in the tumor microenvironment
while sparing normal tissues. Our innovative pipeline consists of
pre|CISION(®) peptide drug conjugates (PDC) or Affimer(®) drug conjugates
(AffDC) that leverage the tumor-specific release mechanism, providing unique
benefits over traditional antibody drug conjugates.

 

About the pre|CISION(®) Platform

The pre|CISION(®) platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumors compared
with healthy tissues. The pre|CISION(®) platform harnesses this tumor
specific protease to cleave pre|CISION(®) peptide drug conjugates and
pre|CISION(®) antibody/Affimer(®) drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and reducing
systemic exposure and toxicity, allowing dosing to be optimized to deliver the
best outcomes for patients.

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEKLBBEKLZBBZ